Technologies

Developments in molecular and genomics technologies are dramatically improving the opportunities for development of more effective cancer therapeutics. At Eurofins Viracor we offer a broad range of molecular and genomic services to support translational and precision medicine approaches to clinical development.

Molecular

Polymerase chain reaction (PCR) technology is the gold standard in molecular testing.

With a wide range of viral and bacterial targets, our clients have access to a broad menu of real-time PCR and quantitative assays for pathogen detection and monitoring, biodistribution and shedding.

Our PCR technology expertise includes: qPCR, RT-PCR, TEM-PCR, ddPCR; and extends across a variety of applications and therapeutic areas.

Genomics

Eurofins Viracor’s capabilities for supporting clinical studies with genomics testing includes:

• Gene expression profiles for detecting and characterizing mutations/biomarkers
• Predictive biomarker assays (whole exome or RNA sequencing)
• Microarray-based RNA expression assays

• Sequencing (NextGen & Sanger)
  • Sequencing Viral Genotyping (including drug resistant markers)
  • Comprehensive targeted NGS panels or tumor profiling assays to detect known and emerging biomarkers
  • Our PanCancerIQ Genomic Profiling Panel (Illumina TSO500)

• nanoString technology
  • With the addition of our new nCounter® Pro Analysis System we now offer our clients this unique,  high-performance digital gene expression capability for a variety of applications.